ALBUM ANALYTICS

Luxury Disease by ONE OK ROCK

Peak position #60

Executive Summary

AI-generated performance analysis

B

Good

This album achieves a B (Good) chart performance rating, peaked at #60.

"Luxury Disease" by ONE OK ROCK is a 15-track album that demonstrates strong chart presence on Apple Music.

The album has spent 341 days on the Top 100 chart.

Released on September 9, 2022.

Key Highlights
  • Peak: #60
  • 341 days on chart
  • 15 tracks
  • Genre: ロック

Key Insights

AI-generated analysis based on chart performance

Exceptional Chart Longevity

With 341 days on the chart (16.2x the average album), this demonstrates sustained audience interest well beyond typical performance.

Consistent Performance

With a 81/100 stability score ("Stable"), this album maintains a steady chart position, suggesting reliable streaming from a dedicated listener base.

Hot Streak Active

65 consecutive days on the chart (best: 128) demonstrates sustained listener engagement without any gaps in chart presence.

Chart Performance Factors

Key metrics driving this album's chart success

26.1/40
Overall Score

Chart Performance

4.1/10

Peak position achieved on the album charts

  • Peak position: #60
  • Peak date: Apr 4, 2026

Chart Longevity

10/10

Total duration on the album charts

  • 16.2x longer than average album
  • 341 total days on chart
  • 128 max consecutive days

Chart Stability

7/10

Consistency of chart position

  • Very stable chart performance
  • Stability index: 88/100

Current Momentum

5/10

Recent chart movement trend

  • Stable chart position
  • Consistent performance
Overall Performance65%

Solid performance with room for growth in some areas.

Category Benchmark

Performance compared to other charting albums

Top 50%
Peak Position
Top 65%
#60actualvs #60 avg

20% below avg

Days on Chart
Top 1%
341 daysactualvs 21 days avg

16.2x higher than avg

Stability Index
Top 25%
88/100actualvs 45/100 avg

2.0x higher than avg

Above average performance compared to charting albums content.

Chart History & Insights

Performance over time

Declining
#80
Peak
#100
Current
0
Top 10
0
Top 50

Currently ranked #100. Peak was #80. Ranking is declining.

Peak reached on Sep 6, 2026

Album Info

Apple Music Reference

Source content being analyzed

Open
Luxury Disease

Luxury Disease

ONE OK ROCK

Sep 9, 2022
Luxury Disease
On Chart

Luxury Disease

E

ONE OK ROCK

15 tracks
9/9/2022
ロックミュージック

Daily Rank

Not charting today

All-Time Rank

#232

Score: 5,130

Peak Position

#60

Apr 4

Days on Chart

341

49 weeks

Performance Breakdown
Top 100341 days
Top 100 days
Top 30 days
#10 days

Current Streak

65d

Best: 128d

Avg Position

#96.1

Last 30 days

7-Day Trend

Stable

Stability

Stable

81/100

Ranking History
Last 18 days performance in Japan
#1#51#100
Aug 12Sep 10
Detailed Statistics
First Charted3/30/2026
Last Charted9/10/2026
Charting Duration165 days
Days to Peak5 days
Days at #10
Days in Top 30
Days in Top 100
Days in Top 100341
All-Time Score
5,130

points

Ranked #232 all-time

Album Information
ArtistONE OK ROCK
Tracks15 songs
TypeAlbum
Released9/9/2022
Genreロック, ミュージック
Recent Rankings
#100
Sep 10
#99
Sep 9
#94
Sep 8
#90
Sep 7
#80
Sep 6
#86
Sep 5
#98
Sep 4
#100
Sep 2
#100
Sep 1
#100
Aug 26
#98
Aug 25
#100
Aug 21
#100
Aug 20
#98
Aug 19

About Rankings

Rankings are based on Apple Music Top 100 charts in Japan. Updated daily.

About This Analytics Report

Official Data

This report is generated by Top1Trend's analytics engine, which tracks Apple Music trending data across 30+ regions since 2024. All metrics are derived from official chart positions via the official Apple Music API.

Data Source
Apple Music API
Last Updated

Sep 10, 2026, 2:00 AM

Tracking Since

2026-03-30

Region

jp

Official API DataReal-time UpdatesHistorical Archives

Top1Trend is an independent analytics service and is not affiliated with, endorsed by, or sponsored by Apple Music. All trademarks belong to their respective owners. Data accuracy depends on platform API availability and may have slight delays from real-time values.